10-Q: Journey Medical Reports Mixed Q2, Launches Emrosi

Journey Medical Corporation reported a slight revenue increase for Q2 2025 driven by the Emrosi launch, but faces recurring losses and a 'going concern' warning.

Summary

• Total net product revenue for the three months ended June 30, 2025, was $15.0 million, a 1% increase from $14.9 million in the same period of 2024.
• For the six months ended June 30, 2025, total net product revenue increased by 1% to $28.2 million from $27.9 million in the prior year period.
• Net loss for the three months ended June 30, 2025, increased to $3.8 million from $3.4 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, improved significantly to $7.9 million from $13.8 million in H1 2024.
• Emrosi, a newly approved product for rosacea, contributed $2.8 million in net product revenue in Q2 2025 and $4.9 million in H1 2025.
• Accutane revenue decreased by 41% in Q2 2025 to $3.4 million and by 39% in H1 2025 to $7.1 million, primarily due to market competition.
• Research and development costs were negligible in Q2 and H1 2025, down from $0.9 million and $8.8 million respectively in 2024, following Emrosi's approval.
• Selling, general and administrative expenses increased by 15% in Q2 2025 to $11.9 million and by 20% in H1 2025 to $22.4 million, driven by Emrosi's commercialization.
• Interest expense increased by 66% in Q2 2025 to $0.9 million and by 65% in H1 2025 to $1.8 million, due to a higher principal balance on the SWK Credit Facility.
• Cash and cash equivalents remained stable at $20.3 million as of June 30, 2025, compared to December 31, 2024.
• Working capital decreased to $10.8 million at June 30, 2025, from $13.0 million at December 31, 2024.
• The company issued 834,722 shares of common stock under its At-the-Market (ATM) offering program, generating net proceeds of $4.1 million during the six months ended June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning, recurring losses, and declining sales of key legacy products. While the launch of Emrosi and improved six-month net loss are positive, they are overshadowed by the fundamental liquidity and profitability concerns, and the need for future capital raises.

Positives

• Successful U.S. commercial launch of Emrosi, contributing $2.8 million in Q2 2025 and $4.9 million in H1 2025.
• Significant reduction in net loss for the six-month period ended June 30, 2025, to $7.9 million from $13.8 million in the prior year.
• Improved net cash used in operating activities for the six-month period, decreasing to $3.8 million from $10.2 million.
• Inclusion in the Russell 2000 and Russell 3000 Indexes effective June 27, 2025, enhancing market visibility.
• Compliance with financial covenants under the SWK Credit Facility as of June 30, 2025.

Negatives

• Recurring losses raise substantial doubt about the company's ability to continue as a going concern for at least twelve months from the financial statement issuance date.
• Working capital decreased to $10.8 million at June 30, 2025, from $13.0 million at December 31, 2024.
• Accutane revenue significantly declined by 41% in Q2 2025 and 39% in H1 2025 due to increased market competition.
• Amzeeq and Zilxi revenues also decreased by 27% and 31% respectively in Q2 2025.
• Increased interest expense by 66% in Q2 2025 and 65% in H1 2025 due to a higher principal balance on the term loan.
• Gross-to-net sales accruals increased by $4.1 million in Q2 2025 and $4.6 million in H1 2025, primarily due to Emrosi's coupon rebate allowance.

Risks

• Products and product candidates are subject to time and cost-intensive regulation and clinical testing, potentially hindering successful development or commercialization.
• A substantial portion of sales derive from products without patent protection or subject to generic competition, which could adversely impact operating income.
• Operating in a heavily regulated industry, with unpredictable impacts from future legislation or administrative actions.
• Revenue is highly dependent on dermatology products, making operating results vulnerable to setbacks in their sales.
• Competition from generic versions and new competitor products could limit commercial opportunity and profitability.
• Risk that products may not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations.
• Dependence on the ability to identify, develop, and acquire or in-license products and integrate them successfully.
• Success of the business, including financing and revenue generation, depends on the successful commercialization of Emrosi and future product candidates.
• Clinical drug development is expensive, time-consuming, and uncertain, with trials potentially failing to demonstrate safety and efficacy.
• Competitors could develop and commercialize products similar or identical to existing ones.
• Risks related to the protection of intellectual property and the potential inability to maintain sufficient patent protection.
• Business and operations could suffer from computer system failures, cyber-attacks, or cybersecurity deficiencies.
• Effects of major public health issues, epidemics, or pandemics on product revenues and clinical trials.
• Potential need to raise additional capital to fund operations and strategic initiatives.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses.
• Fortress Biotech, Inc. controls a voting majority of common stock, which could be detrimental to other shareholders.
• Business may be materially adversely affected by the imposition of duties, tariffs, and other trade barriers, especially given significant imports from countries like India.
• Products may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives (e.g., Affordable Care Act, Inflation Reduction Act of 2022, 'most-favored nation' pricing), which could harm the business.
• Increased Congressional scrutiny of the FDA's approval process and staffing cuts at the FDA may delay or prevent marketing approval and lead to more stringent post-marketing requirements.

Future Outlook

The company is evaluating market conditions, its liquidity profile, and financing alternatives, including out-licensing arrangements, to enhance its capital structure. It may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives. The company is also evaluating the impact of the recently signed 'One Big Beautiful Bill Act' (OBBBA) on its financial statements.

Management Comments

• We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients.

Industry Context

The company operates in the highly regulated U.S. dermatological pharmaceutical market, which is subject to intense competition from both branded and generic products. The industry faces ongoing pressures from healthcare reform initiatives, including government efforts to control drug pricing through measures like the Inflation Reduction Act and potential 'most-favored nation' pricing. The company's strategy of acquiring and commercializing FDA-approved products is common in this sector, but it must contend with the lifecycle of products, including the impact of generic competition on older drugs like Accutane, while investing in the launch of new products like Emrosi. The reliance on third-party manufacturing and distribution is also a standard industry practice.

Comparison to Industry Standards

• The company's reliance on a portfolio of acquired FDA-approved products is a common strategy among specialty pharmaceutical companies, similar to how companies like Bausch Health Companies Inc. (BHC) or Almirall S.A. manage their dermatology portfolios, though Journey Medical's scale is significantly smaller.
• The decline in Accutane sales due to generic competition is a typical challenge faced by pharmaceutical companies as products lose patent exclusivity, mirroring experiences seen with drugs like Lipitor (Pfizer) or Humira (AbbVie) as biosimilars/generics entered the market.
• The increase in gross-to-net sales accruals, particularly for coupon rebates related to a new product launch like Emrosi, is a standard commercial strategy in the pharmaceutical industry to drive adoption, comparable to launch strategies employed by companies introducing new therapies.
• The 'going concern' warning, while concerning, is not unique to smaller, commercial-stage pharmaceutical companies that are still building profitability and require significant capital for product development and commercialization, often seen in early-stage biotech firms before achieving consistent positive cash flow.

Corporate Governance

Legal Proceedings

• No material legal proceedings are pending against the company, other than routine actions, administrative proceedings, and other actions not deemed material, that are expected to have a material adverse effect on financial condition, results of operations, or cash flows.

Related Party Transactions

• The company is a majority-owned subsidiary of Fortress Biotech, Inc. (Fortress).
• Under a Shared Services Agreement, the company reimburses Fortress for salary and benefit costs of certain employees based on actual hours worked on Journey-related projects, and for various payroll-related and selling, general and administrative costs.
• Related party expenses to Fortress were approximately $10,000 for Q2 2025 and $22,000 for H1 2025.
• The 'due to related party' liability increased to $0.8 million at June 30, 2025, from $0.5 million at December 31, 2024.

Stakeholder Impact

• Shareholders face potential dilution from ongoing At-the-Market (ATM) equity offerings and future capital raises, as well as the risk associated with the 'going concern' warning.
• Shareholders may benefit from increased visibility and potential liquidity due to the company's inclusion in the Russell 2000 and Russell 3000 Indexes.
• Employees are impacted by share-based compensation plans, including stock options and restricted stock units.
• Customers and patients benefit from the commercial launch and availability of Emrosi for rosacea treatment.
• Creditors, particularly SWK Funding LLC, are impacted by the company's debt obligations and its ability to meet repayment schedules, though the company is currently in compliance with covenants.
• Suppliers and partners may face uncertainty due to the 'going concern' warning, although the company continues to operate and launch new products.

Next Steps

• Continue commercialization of Emrosi in the U.S. with the existing commercial team.
• Evaluate market conditions, liquidity profile, and financing alternatives to enhance capital structure.
• Potentially raise capital through debt or equity financings to expand product portfolio and for other strategic initiatives.
• Monitor and evaluate the impact of the 'One Big Beautiful Bill Act' (OBBBA) on financial statements.
• Begin quarterly principal repayments on the SWK Term Loans in February 2026, or February 2027 if trailing twelve-month revenue exceeds $70.0 million by December 31, 2025.

Key Dates

Recommendation

Despite the successful launch of Emrosi and an improved net loss for the six-month period, the explicit 'substantial doubt about the company's ability to continue as a going concern' is a critical red flag for investors. The decline in working capital, increased quarterly net loss, and significant revenue drops in key legacy products (Accutane, Amzeeq, Zilxi) indicate underlying operational challenges and a precarious financial position. While the ATM offering provides some liquidity, the recurring losses suggest a continued need for external financing, which could lead to further dilution. The risks associated with generic competition, healthcare reform, and the overall financial instability outweigh the positives of the new product launch and index inclusion, making the stock a high-risk proposition with significant downside potential.

Keywords

Dermatology, Pharmaceuticals, SEC Filing, 10-Q, Emrosi, Qbrexza, Accutane, FDA Approved, Specialty Pharma, Biotech, Financial Results, Going Concern, SWK Credit Facility, ATM Offering, Product Launch, Generic Competition